Clorox: A Strong Quarter, but the Price Requires More

The Quarter in Context

For the three months ended September 30, 2026, Clorox reported net sales of $1.905 billion, up 33.3% from $1.429 billion in the year-ago quarter. Gross profit rose 29.2% to $770 million, while earnings attributable to Clorox increased to $170 million from $80 million. Diluted EPS was $1.39 versus $0.65, and diluted weighted-average shares declined to 122.0 million from 123.0 million.

The comparison is acquisition-distorted. Clorox completed its $2.147 billion cash acquisition of GOJO on April 1, 2026, and GOJO now operates as Clorox Purell ProCare within Health and Wellness. Management reported GAAP Health and Wellness sales growth of 62%, but organic growth of 23% after removing a 39-point acquisition effect. Company-wide organic sales growth was 18%, versus 33% on a GAAP basis. These are different evidence classes: the first is a reported accounting result, while the second is management’s supplemental measure of underlying growth.

Reported earnings also benefited from a 16.4% effective tax rate, versus 23.4% a year earlier, principally because of an international legal-entity reorganization. That tax effect supports period earnings but does not establish a repeatable source of operating growth. Meanwhile, acquisition and integration costs were $26 million, and management’s adjusted EBIT was $284 million versus $160 million; adjusted EBIT is a non-GAAP measure, not a substitute for GAAP profit.

The quarter therefore looks strong on the surface, but its entry point is incomplete. It combines acquired revenue, an acquired manufacturing and distribution base, tax benefits, and management adjustments. The key question is not whether Clorox can grow reported sales in this quarter; it is whether the combined company can produce durable mid-cycle cash flow after integration, capital expenditure, interest, and debt repayment.

Business Model and Profit Engine

Clorox sells consumer and professional cleaning, disinfecting, sanitizing, hygiene, food, pet, grill, and personal-care products. Retailers, grocery outlets, clubs, dollar stores, home-improvement retailers, drug and pet stores, military channels, e-commerce businesses, and distributors pay for branded products, while healthcare and other institutional customers buy professional hygiene solutions and dispensing systems. Consumer purchases are largely transactional; the professional model adds installed-base and refill characteristics that can create recurring demand.

The four reportable segments are Health and Wellness, Household, Lifestyle, and International, with Corporate and Other. Health and Wellness includes home cleaning, disinfecting, laundry additives, Purell and GOJO skin sanitization, and professional cleaning and disinfecting products. Household contains Glad bags and wraps, Fresh Step and Scoop Away cat litter, and Kingsford grilling products. Lifestyle includes Hidden Valley dressings, dips, seasonings and sauces, Brita filtration, and Burt’s Bees personal care. International operates across approximately 25 countries or territories, while the company sells in roughly 95 markets.

Revenue becomes gross profit through product pricing, manufacturing costs, raw materials, packaging, freight, and mix. In the September 2026 quarter, cost of products sold was $1.135 billion, producing a 40.4% gross margin, compared with 41.7% a year earlier. Selling and administrative expenses were $290 million, advertising was $190 million, and R&D was $29 million. Interest expense rose to $52 million from $23 million following acquisition financing. Gross profit therefore covered substantial brand, administrative, research, and financing costs, but the available GAAP data do not include a directly tagged operating-income line, so operating margin and segment operating profit should not be inferred from incomplete fields.

The principal economics are brand-based and moderately capital intensive rather than toll manufacturing. Advertising and selling costs support demand; plants, inventory, and logistics absorb cash; GOJO adds a different professional channel with dispensing-system and regulatory characteristics. Gross profit can benefit from pricing and mix, but raw-material, freight, labor, and retailer pressures can absorb it. The filing identifies single-source suppliers and category volatility as risks, while also noting that commodity hedges generally mature within two years and cover only part of forecast requirements.

Segment economics are not fully available in the excerpted evidence: segment sales growth is provided, but complete segment margins, customer cohorts, and the split between maintenance and growth capital expenditure are not. That prevents a precise test of cross-subsidies and unit economics. Observable conditions that would weaken the profit engine include falling organic sales, gross-margin contraction without corresponding cost relief, higher interest expense, or GOJO integration costs that continue without cash benefits.

Earnings Quality and Cash Conversion

For the three months ended September 30, 2026, operating cash flow was $143 million and capital expenditure was $38 million, producing an accounting free-cash-flow proxy of $105 million. The same calculation for the quarter ended September 30, 2025 was $93 million of operating cash flow, $36 million of capital expenditure, and a $57 million proxy. For the twelve months ended September 30, 2026, operating cash flow was $425 million and capital expenditure was $159 million, leaving a $266 million accounting free-cash-flow proxy.

This proxy is not normalized owner earnings. The filing does not separate maintenance from growth capital expenditure, so it cannot support a maintenance-capex earnings measure. Stock-based compensation was $9 million in the quarter and $58 million over the trailing twelve months. A Buffett-style owner-earnings analysis would need to decide whether to deduct that recurring economic cost and how to normalize acquisition, integration, working-capital, and cycle effects. Here, reported cash less total capital expenditure is the auditable base used for valuation.

Cash conversion was positive but not effortless. In the September 2026 quarter, receivables released $42 million and inventory consumed $4 million, while accounts payable and accrued liabilities used $68 million and taxes used $63 million. Operating cash flow therefore benefited from receivable collection but was restrained by supplier accruals and taxes. At September 30, 2026, current receivables were $745 million and inventory was $774 million, indicating meaningful working capital tied up in the business.

The supply-chain finance program also matters. Suppliers had $229 million of payables in the program at September 30, 2026. Clorox states that supplier participation does not change its payment obligations or affect its balance sheet or liquidity directly, although extended payment terms affect operating cash flow. This is not hidden debt on the disclosed balance sheet, but it is a cash-conversion consideration because payment timing supports liquidity.

Cash was $184 million at September 30, 2026. Total debt was $5.158 billion on the selected current-and-noncurrent carrying-value basis: $1.175 billion of notes and loans payable, $1 million of current long-term debt maturities, and $3.982 billion of long-term debt. The component long-term total is therefore $3.983 billion, and no additional reported aggregate is available to reconcile against it. Subtracting cash gives net debt of $4.974 billion. Clorox did have $1.964 billion of revolving credit agreements with no borrowings at quarter-end and was in compliance with the 4.0 interest-coverage covenant.

Business Quality, Moat, and Industry Position

On the available evidence, the company is best described as an important participant, not a demonstrated core supply-chain bottleneck. This classification describes strategic position only; it is not independent proof of a moat or valuation upside.

Clorox’s moat evidence is principally brand leadership, category position, distribution, and—in the professional business—installed dispensing systems. The company says more than 80% of sales come from brands holding the No. 1 or No. 2 market position in their categories. It sells across many channels and markets, which reduces dependence on one retailer, and the GOJO acquisition adds an established professional distribution network and installed base. These are observable competitive assets, not proof of permanent pricing power.

The supply-chain position is that of an important branded manufacturer rather than a scarce upstream input supplier. Upstream, Clorox depends on raw materials, packaging, energy, logistics, labor, and some single-source suppliers. Midstream, it manufactures and distributes branded products through its own network and GOJO’s professional channel. Downstream, it sells mainly through retailers and distributors to consumers, and through healthcare and institutional customers to organizations with sanitation and hygiene needs.

Its value capture depends on brand relevance, shelf placement, product efficacy, regulatory compliance, and, in professional hygiene, installed systems that can encourage refill purchases. Substitution is possible: consumers can choose another brand, retailers can private-label, and institutional buyers can change suppliers. Capacity elasticity appears greater for conventional consumer products than for specialized professional systems, but the evidence does not quantify switching costs, customer concentration, order visibility, or supplier concentration.

The bottleneck score is 3 out of 5: brands, distribution, regulatory capability, and dispensing systems create some qualification and familiarity advantages, but the company is not demonstrably indispensable to final demand. Strategic importance does not itself establish moat depth or valuation upside. Evidence that would strengthen the moat includes sustained organic growth above category trends, stable or expanding gross margin through raw-material cycles, high renewal or refill behavior in professional products, and resilient customer retention. Warning signs would include repeated share loss, promotional dependence, rising retailer concentration, or acquisition synergies that appear only in adjusted metrics.

Management and Capital Allocation

Observable conduct shows both continuity and risk-taking. Clorox paid $151 million of dividends in the September 2026 quarter and $603 million over the trailing twelve months, while making no open-market share repurchases in the quarter after spending $129 million in the year-ago period. It paid $151 million of dividends during the quarter while cash was only $184 million, funded partly by an $89 million net increase in notes and loans payable.

The GOJO purchase was funded through commercial paper and new debt. Its preliminary purchase price included $716 million of goodwill, $487 million of trademarks, and $569 million of other intangible assets. Those assets do not represent cash, and their value depends on future customer, regulatory, and competitive performance. Clorox also recorded $28 million of environmental remediation liabilities, while the Burt’s Bees trademark had only 20% or less excess fair value over carrying value after the fiscal 2026 review and carried a $322 million value at September 30, 2026.

Management’s strategic rationale—expanding health and hygiene and adding professional recurring demand—is plausible. The financing choice is less forgiving: acquisition debt fixed the purchase price but raised interest expense, reduced balance-sheet flexibility, and made shareholder distributions compete with deleveraging. Future buybacks at a high market price could destroy value even if they offset dilution.

The cultural evidence is mixed. Management completed a major ERP transformation, reports effective disclosure controls, provides useful GAAP-to-non-GAAP reconciliations, and identifies acquisition and concentration risks candidly. Against that, a $2.147 billion acquisition completed after a year of declining fiscal 2026 sales and earnings raises the execution burden. The filing also references CEO succession and integration risks. Culture should ultimately be judged by whether management converts integration spending into cash, protects the balance sheet, and avoids sacrificing long-term brand quality for short-term adjusted results.

Valuation and What the Market Already Expects

As of November 3, 2026, CLX closed at $89.90, giving a market capitalization of $10.872 billion. That is already an equity value; adding market capitalization to cash and subtracting debt would double-count the equity bridge. The relevant enterprise value is approximately $15.846 billion, calculated as market capitalization plus the $4.974 billion September 30, 2026 net-debt adjustment.

The trailing accounting free-cash-flow proxy of $266 million is only about 2.4% of market capitalization. That low cash-flow yield is the clearest valuation burden. It does not prove the shares must fall, because the quarter includes acquisition effects and free cash flow may improve, but it means investors are paying for substantial future normalization and growth.

A reverse cash-flow calculation indicates that the dated market price appears to require roughly 19.4% annual free-cash-flow growth from the current base, before discounting, under the calculation’s conventions. This is a model calculation, not company guidance. It illustrates the scale of operating normalization required: sustained organic growth, successful GOJO integration, favorable pricing and mix, adequate capacity utilization, and no prolonged working-capital or capital-expenditure drag.

The conclusion is not that Clorox lacks value. It is that the market price requires a favorable path through a leveraged acquisition and a mixed consumer environment. The cash-flow yield, acquisition-funded debt, negative Clorox stockholders’ equity, and high terminal-value dependence in a discounted model all argue against treating the shares as a margin-of-safety purchase at this price.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is reported operating cash flow less reported total capital expenditure: an accounting cash-flow proxy, not normalized sustainable earnings or maintenance-capex owner earnings. Every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and the supplied same-date balance-sheet adjustment. The supplied current cash and debt inputs reconcile to the dated adjustment shown below. Missing inputs are never treated as zero; an unavailable bridge would block this calculation. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly 19.4% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. For positive scenario equity values, negative margin of safety means the current market capitalization exceeds the scenario value. For zero or negative scenario equity values, a margin-of-safety percentage is not meaningful; the obligations exhaust the modeled enterprise value.

Five Value-Investing Lenses

Benjamin Graham Lens

Clorox does not pass a conservative Graham downside floor at $89.90. The September 30, 2026 balance sheet had $184 million of cash, $5.158 billion of total debt, $4.974 billion of net debt, and negative $39 million Clorox stockholders’ equity. Liquidity facilities and covenant compliance help, but they do not make the capital structure conservative. Trailing EPS of $4.87 is reported data, yet a famous brand, cyclical earnings, and acquisition accounting cannot substitute for margin of safety.

Benjamin Franklin Lens

Franklin’s modern lesson is disciplined compounding and opportunity cost. Clorox paid $603 million of trailing dividends while debt rose and no quarter repurchases occurred. The company chose GOJO, brand investment, ERP spending, and a regular dividend over balance-sheet conservatism. That can create value if integration produces durable cash, but the opportunity cost is high: every additional dollar of acquisition debt and integration expense competes with deleveraging and reinvestment. The dividend is attractive only if it is sustainable through a weaker cycle.

Warren Buffett Lens

The owner-earnings question centers on $266 million of trailing operating cash flow less $159 million of total capital expenditure. That is an accounting free-cash-flow proxy, not normalized owner earnings. Because maintenance and growth capital expenditure are not separated, and stock compensation averages $58 million over the trailing year, sustainable owner economics are uncertain. Clorox’s brands and GOJO’s installed systems may support persistence, but leverage, interest, acquisition costs, and capital intensity weaken the margin of safety. Capital allocation is mixed, not clearly exemplary.

Charlie Munger Lens

Munger’s inversion asks what could make an apparently strong quarter fail. The likely wrong assumption is that GOJO’s reported sales growth will convert into proportionate owner cash after integration, interest, working capital, and capital expenditure. Incentive checks are imperfect: management uses adjusted EBIT for internal assessment and compensation, although it reconciles that measure and identifies excluded costs. Attention bias is high because reported growth is strong, while the harder signals are a low cash-flow yield, acquisition-funded debt, negative book equity, and a valuation that requires prolonged compounding.

Li Lu Lens

Clorox is understandable at a high level: sell branded household and professional hygiene products, invest ahead of demand, and convert gross profit into cash after factory, channel, and working-capital needs. The circle-of-competence question is whether the market can judge category-specific pricing, promotion, retailer inventory, and professional hygiene durability from public filings alone; those details are incomplete here. Brands, No. 1 or No. 2 category positions, and dispensing systems are credible durable advantages, but culture and integration must be proven through cash outcomes rather than slogans.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

First, GOJO could fail to convert acquired growth into cash. Observable indicators would be persistent acquisition and integration costs, rising working capital, weak free cash flow, or impairment of acquired goodwill and intangibles. Second, brand pricing could weaken: falling organic sales, declining gross margin, or promotional pressure would show that the moat is less powerful than category position suggests. Third, leverage could constrain resilience: total debt failing to decline, interest coverage moving toward the 4.0 covenant threshold, or restricted dividend and buyback capacity would weaken downside protection.

Other thesis breakers include customer concentration or channel change in the professional business, single-source supply disruption, raw-material inflation that cannot be passed through, regulatory or product-liability events, and environmental remediation exceeding recorded liabilities. The Burt’s Bees trademark’s narrow impairment cushion is another specific warning: a further reduction in estimated fair value could signal weaker brand economics or acquisition-related risk.

The most likely wrong assumption is that a strong first quarter proves a durable growth and cash-generation trajectory after GOJO. The opportunity cost is severe: buying at $89.90 while offering only a low trailing cash-flow yield and accepting net debt of $4.974 billion. Evidence that would change the conclusion would include sustained organic growth, materially stronger cash conversion, and debt reduction that make enterprise value more resilient without requiring heroic assumptions. Conversely, the bearish view should be abandoned if free cash flow expands consistently enough to reduce both leverage and the market’s implied growth burden.

Investment Conclusion

Clorox is a worthwhile business to monitor but an unattractive price to underwrite at November 3, 2026. The September quarter showed real operating progress, but acquisition accounting, tax benefits and management adjustments limit what can be inferred from headline growth. More importantly, the dated $10.872 billion market capitalization materially exceeds the base valuation scenario, while the low trailing cash-flow yield demands strong multi-year execution and carries little protection against integration, cyclicality, or leverage disappointments.

The conclusion is Overvalued, not because the company lacks franchise value, but because investors are being asked to pay today for cash generation that has not yet been demonstrated. A lower market price, stronger evidence of durable free cash flow after GOJO, or meaningful deleveraging could change the balance. This analysis is for educational use, not personalized investment advice, and readers should conduct their own due diligence.